Combination therapy for recurrent mouth and throat cancer
Part of Cancer clinical trials.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) before and after surgery for people whose mouth or throat cancer has returned after previous treatment. The goal is to see if this approach can help shrink or control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell carcinoma of the mouth or throat that has come back after at least 16 weeks since your last treatment.
- You are between 18 and 75 years old.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- A doctor believes you are able to have surgery to remove the cancer.
- You have not had certain immune therapies (like anti-PD-1 or anti-PD-L1) before.
- You have no active infections, liver problems, or other serious health conditions.
- You agree to use effective birth control during the study and for 12 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This trial tests whether adding a type of radiation therapy (SBRT) to chemoimmunotherapy before surgery helps people with advanced mouth or throat cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This trial tests whether giving immunotherapy (sintilimab) together with chemotherapy before surgery can help treat oral cavity cancer. The goal is to shrink the tumor and possibly improve outcomes for patients with early-stage cancer that hasn't spread.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Oropharyngeal Squamous Cell Carcinoma (SCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.